Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database [PDF]
Frontiers in MedicineObjectiveDenosumab and romosozumab are two biological agents with potential immunomodulatory effects commonly used to treat osteoporosis. This study aimed to compare the safety of these two drugs using the FDA Adverse Event Reporting System (FAERS) with ...
Jian Sun +5 more
doaj +2 more sources
Effectiveness of romosozumab following prior raloxifene treatment in primary osteoporosis: An observational study [PDF]
Bone ReportsRomosozumab is an anti-sclerostin antibody that increases bone formation and decreases bone resorption. It has been available for patients at high risk of osteoporotic fractures in Japan since 2019.
Kazuaki Mineta +4 more
doaj +2 more sources
Romosozumab and cardiovascular safety in Japan
Osteoporosis and Sarcopenia, 2021 Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable.
Yasuhiro Takeuchi
doaj +4 more sources
Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia, 2018 Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality ...
Michael R. McClung
doaj +5 more sources
High-dose romosozumab promoted bone regeneration of critical-size ulnar defect filled with demineralized bone matrix in nonhuman primates [PDF]
Journal of Orthopaedic TranslationBackground: Large bone defects are challenging to manage clinically and usually require treatment with bone graft or bone graft substitute. This study evaluated the effect of romosozumab, a sclerostin antibody, in combination with demineralized bone ...
Xiaodong Li +7 more
doaj +2 more sources
Risk factors and reasons for romosozumab nonadherence in a case-control study [PDF]
Scientific ReportsRisk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study
Ting-Chien Tsai +6 more
doaj +2 more sources
When skin reactions interrupt bone therapy: severe cutaneous adverse reaction to romosozumab leading to treatment discontinuation [PDF]
European Journal of Case Reports in Internal MedicineBackground: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials ...
Luis Antonio Rodriguez Arrieta +5 more
doaj +2 more sources
Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures [PDF]
Neurospine, 2023 Objective Romosozumab is increasingly employed to manage osteoporosis. However, no studies have analyzed its effects on recent osteoporotic vertebral compression fractures (OVCFs).
Danbi Park +7 more
doaj +1 more source
Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa
Osteoporosis and Sarcopenia, 2023 Objectives: This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism. Methods: In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and ...
Kazuki Fujimoto +6 more
doaj +1 more source
Bone Reports, 2022 Objectives: As romosozumab has both bone anabolic and antiresorptive effects, it is not clear which patient groups are more likely to have decreased calcium concentrations when treated with romosozumab. The aim of this study was to investigate the impact
Hiroyuki Inose +8 more
doaj +1 more source